PL367267A1 - Antineoplastic combinations - Google Patents

Antineoplastic combinations

Info

Publication number
PL367267A1
PL367267A1 PL02367267A PL36726702A PL367267A1 PL 367267 A1 PL367267 A1 PL 367267A1 PL 02367267 A PL02367267 A PL 02367267A PL 36726702 A PL36726702 A PL 36726702A PL 367267 A1 PL367267 A1 PL 367267A1
Authority
PL
Poland
Prior art keywords
antineoplastic combinations
antineoplastic
combinations
Prior art date
Application number
PL02367267A
Other languages
English (en)
Polish (pl)
Inventor
Gary Dukart
James Joseph Gibbons Jr.
Original Assignee
Wyeth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth filed Critical Wyeth
Publication of PL367267A1 publication Critical patent/PL367267A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL02367267A 2001-06-01 2002-05-29 Antineoplastic combinations PL367267A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29523601P 2001-06-01 2001-06-01
US29519001P 2001-06-01 2001-06-01

Publications (1)

Publication Number Publication Date
PL367267A1 true PL367267A1 (en) 2005-02-21

Family

ID=26968972

Family Applications (1)

Application Number Title Priority Date Filing Date
PL02367267A PL367267A1 (en) 2001-06-01 2002-05-29 Antineoplastic combinations

Country Status (17)

Country Link
EP (1) EP1392286A2 (https=)
JP (1) JP2004532883A (https=)
KR (1) KR100875611B1 (https=)
CN (1) CN100496485C (https=)
AU (2) AU2002259309B2 (https=)
BR (1) BR0210101A (https=)
CA (1) CA2447732A1 (https=)
CO (1) CO5540294A2 (https=)
EA (1) EA007530B1 (https=)
HU (1) HUP0400006A2 (https=)
IL (1) IL158800A0 (https=)
MX (1) MXPA03010907A (https=)
NO (1) NO20035317L (https=)
NZ (1) NZ529877A (https=)
PL (1) PL367267A1 (https=)
SG (1) SG153647A1 (https=)
WO (1) WO2002098416A2 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL409579A1 (pl) 2001-02-19 2015-03-02 Novartis Ag Leczenie raka
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
AR046194A1 (es) 2003-11-04 2005-11-30 Mayo Foundation Metodo de tratamiento del linfoma de celulas del manto
ES2364495T3 (es) 2005-02-03 2011-09-05 The General Hospital Corporation Método para tratar cáncer resistente a gefitinib.
JP2009514870A (ja) * 2005-11-04 2009-04-09 ワイス ｍＴＯＲインヒビター、ハーセプチン、および／またはＨＫＩ−２７２の抗悪性腫瘍性組み合わせ
RU2487711C2 (ru) * 2005-11-21 2013-07-20 Новартис Аг Лечение нейроэндокринных опухолей
GB0523658D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
US20090023768A1 (en) * 2006-02-24 2009-01-22 Novartis Ag Rapamycin derivatives for treating neuroblastoma
CA2645633A1 (en) * 2006-04-05 2007-11-01 Novartis Ag Combinations of therapeutic agents for treating cancer
WO2008109163A1 (en) * 2007-03-07 2008-09-12 Abraxis Bioscience, Llc. Nanoparticle comprising rapamycin and albumin as anticancer agent
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
ES2692769T3 (es) 2008-06-17 2018-12-05 Wyeth Llc Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina
CN105147713A (zh) 2008-08-04 2015-12-16 惠氏有限责任公司 4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合
SG174382A1 (en) 2009-04-06 2011-11-28 Wyeth Llc Treatment regimen utilizing neratinib for breast cancer
CN103721189A (zh) * 2013-12-27 2014-04-16 刘玉含 一种脑膜瘤护理药物及其制备方法
CN105168204A (zh) * 2015-09-06 2015-12-23 江志鑫 一种含有丝裂霉素的抗结肠癌药物组合物
CN119732959A (zh) * 2024-12-31 2025-04-01 吉林大学 具有mTOR抑制能力的制剂在制备抗肿瘤联合用药物组合物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5066493A (en) * 1978-11-03 1991-11-19 American Home Products Corporation Rapamycin in treatment of tumors
US4401653A (en) * 1981-03-09 1983-08-30 Ayerst, Mckenna & Harrison Inc. Combination of rapamycin and picibanil for the treatment of tumors
ATE135583T1 (de) * 1991-06-18 1996-04-15 American Home Prod Verwendung von rapamycin zur behandlung von t- zellen lymphom/leukämie bei erwachsenen
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
PL409579A1 (pl) * 2001-02-19 2015-03-02 Novartis Ag Leczenie raka

Also Published As

Publication number Publication date
IL158800A0 (en) 2004-05-12
HUP0400006A2 (hu) 2004-04-28
EA200301319A1 (ru) 2004-04-29
SG153647A1 (en) 2009-07-29
NO20035317L (no) 2003-12-22
AU2002259309B2 (en) 2008-05-01
NO20035317D0 (no) 2003-11-28
CO5540294A2 (es) 2005-07-29
CN1646120A (zh) 2005-07-27
EA007530B1 (ru) 2006-10-27
KR100875611B1 (ko) 2008-12-24
AU2008202690A1 (en) 2008-07-10
KR20040025923A (ko) 2004-03-26
NZ529877A (en) 2006-08-31
MXPA03010907A (es) 2004-02-17
BR0210101A (pt) 2004-06-08
CA2447732A1 (en) 2002-12-12
JP2004532883A (ja) 2004-10-28
WO2002098416A2 (en) 2002-12-12
WO2002098416A3 (en) 2003-03-13
EP1392286A2 (en) 2004-03-03
CN100496485C (zh) 2009-06-10

Similar Documents

Publication Publication Date Title
IL159859A0 (en) Antineoplastic combinations
IL160851A0 (en) Thiopene-and thiazolesulfonamides as antineoplastic agents
DE60210819D1 (en) Pyrazolopyridazinderivate
DE60218514D1 (en) Polyolefin-kunststoffrohre
IL158800A0 (en) Antineoplastic combinations
ZA200603888B (en) Antineoplastic combinations
AU2002360430A8 (en) 14-methyl-epothilones
DE60226167D1 (en) Computersystem-e/a-knoten
GB0102319D0 (en) Light-diffuser
GB0100862D0 (en) Reflactron
AU2002313943A8 (en) Electromobile
GB0114007D0 (en) Oilgonucleotides
GB0104111D0 (en) Shopeye
GB0102393D0 (en) Cup-carrier
EP1355643A4 (en) EPOXYVIBSANIN B
GB0112858D0 (en) Matchit
GB0115127D0 (en) Wheelarrow
GB0112053D0 (en) Bacsac
GB0106715D0 (en) Groyne
CA93959S (en) Tilt-latch
HK1060846A (en) Antineoplastic combinations
GB0102877D0 (en) Squeezeasy
GB0104609D0 (en) Tea-light graduator
GB0105453D0 (en) Shopaholics
GB0105454D0 (en) Eye-trek-2001 multimedia-helmet visualiser

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)